Loading
Thioguanine (Tabloid) is an oral chemotherapy tablet used in some regimens to induce and consolidate remission in acute myeloid leukaemia; long-term use is avoided because it damages the liver.
Thioguanine, a sibling of mercaptopurine from the Elion-Hitchings programme, was approved in 1966 for remission induction and consolidation of acute non-lymphocytic leukaemias. It appears in historical AML regimens such as DAT and TAD and in some childhood ALL protocols, but the label advises against maintenance or long-term use because of hepatic sinusoidal obstruction syndrome and nodular regenerative hyperplasia; the UK ALL97 trial confirmed excess liver toxicity when it replaced mercaptopurine in maintenance. Myelosuppression is dose-limiting, and TPMT-deficient patients need dose reduction.
Guanine analogue converted to thioguanine nucleotides incorporated into DNA, causing strand breaks and cell death; inactivated by TPMT.
1.Thioguanine slips into a pocket on its target.
| Region | Year | Indication |
|---|---|---|
| US | 1966 | Remission induction and consolidation of acute non-lymphocytic leukaemias |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Thioguanine" OR ABSTRACT:"Thioguanine" OR TITLE:"Tabloid" OR ABSTRACT:"Tabloid" OR TITLE:"6-TG" OR ABSTRACT:"6-TG" OR TITLE:"Tioguanine" OR ABSTRACT:"Tioguanine") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Thioguanine, not a curated reading list.
Shares Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome, Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia, Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia, International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia and the tag generic.
Shares Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome, Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia, Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia, International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia and the tag generic.
Shares Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia, Acute myeloid leukaemia, Cytotoxic chemotherapy and the tag generic.
Shares Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome, Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia, Acute myeloid leukaemia, Cytotoxic chemotherapy and the tag generic.
Shares Cytotoxic chemotherapy and the tag generic.
Shares International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia, Cytotoxic chemotherapy and the tag generic.
Shares Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations, High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL), Cytotoxic chemotherapy and the tag generic.
Shares Cytotoxic chemotherapy and the tag generic.